Compare Eli Lilly And Co (LLY) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

ZETA trades at $21.34, down 1.57% on the day, with a bullish technical signal from moving averages and strong analyst support (73% buy ratings). The company reported Q1 2026 earnings of $0.14 per share, beating estimates, and is pivoting toward AI infrastructure through partnerships with Palantir and OpenAI. Revenue grew to $1.30 billion in 2025, though net income remained negative at -$31.51 million.

The outlook is positive due to AI-driven growth and strategic partnerships, but risks include margin pressure and integration challenges. The consensus price target of $27.50 suggests significant upside potential if execution aligns with bullish expectations, though negative profitability metrics warrant caution.